These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30028141)

  • 21. (D)-penicillamine increases hepatic oxalate production resulting in hyperoxaluria.
    Baker PW; Bais R; Rofe AM
    J Urol; 1997 Mar; 157(3):1130-5. PubMed ID: 9072557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.
    Cochat P; Hulton SA; Acquaviva C; Danpure CJ; Daudon M; De Marchi M; Fargue S; Groothoff J; Harambat J; Hoppe B; Jamieson NV; Kemper MJ; Mandrile G; Marangella M; Picca S; Rumsby G; Salido E; Straub M; van Woerden CS;
    Nephrol Dial Transplant; 2012 May; 27(5):1729-36. PubMed ID: 22547750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary hyperoxaluria.
    Watts RW
    Contrib Nephrol; 1997; 122():143-59. PubMed ID: 9399058
    [No Abstract]   [Full Text] [Related]  

  • 24. Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type I.
    Hernández-Fernaud JR; Salido E
    FEBS J; 2010 Nov; 277(22):4766-74. PubMed ID: 20977670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design.
    Murray MS; Holmes RP; Lowther WT
    Biochemistry; 2008 Feb; 47(8):2439-49. PubMed ID: 18215067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary hyperoxaluria type III--a model for studying perturbations in glyoxylate metabolism.
    Belostotsky R; Pitt JJ; Frishberg Y
    J Mol Med (Berl); 2012 Dec; 90(12):1497-504. PubMed ID: 22729392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stiripentol identifies a therapeutic target to reduce oxaluria.
    Letavernier E; Daudon M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):394-399. PubMed ID: 32452916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria.
    Morgan SH; Purkiss P; Watts RW; Mansell MA
    Nephron; 1987; 46(3):253-7. PubMed ID: 3306417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic alanine-glyoxylate aminotransferase activity and oxalate metabolism in vitamin B6 deficient rats.
    Nishijima S; Sugaya K; Morozumi M; Hatano T; Ogawa Y
    J Urol; 2003 Feb; 169(2):683-6. PubMed ID: 12544342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1).
    Koul S; Johnson T; Pramanik S; Koul H
    Am J Nephrol; 2005; 25(2):176-82. PubMed ID: 15849465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of endogenous oxalate production: biochemical considerations of the roles of glycollate oxidase and lactate dehydrogenase.
    Bais R; Rofe AM; Conyers RA
    Clin Sci (Lond); 1989 Mar; 76(3):303-9. PubMed ID: 2647367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regressive course of oxalate deposition in primary hyperoxaluria after kidney transplantation.
    Celik G; Sen S; Sipahi S; Akkin C; Tamsel S; Töz H; Hoscoskun C
    Ren Fail; 2010; 32(9):1131-6. PubMed ID: 20863224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria.
    Marangella M; Petrarulo M; Cosseddu D; Vitale C; Linari F
    Am J Kidney Dis; 1992 Jun; 19(6):546-53. PubMed ID: 1595703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II.
    Monico CG; Persson M; Ford GC; Rumsby G; Milliner DS
    Kidney Int; 2002 Aug; 62(2):392-400. PubMed ID: 12110000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations.
    Kanoun H; Jarraya F; Maalej B; Lahiani A; Mahfoudh H; Makni F; Hachicha J; Fakhfakh F
    BMC Nephrol; 2017 Oct; 18(1):303. PubMed ID: 28969594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological approaches in the treatment of primary hyperoxaluria.
    Holmes RP
    J Nephrol; 1998; 11 Suppl 1():32-5. PubMed ID: 9604807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary hyperoxaluria in Coton de Tulear.
    Vidgren G; Vainio-Siukola K; Honkasalo S; Dillard K; Anttila M; Vauhkonen H
    Anim Genet; 2012 Jun; 43(3):356-61. PubMed ID: 22486513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glyoxylate is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells.
    Schnedler N; Burckhardt G; Burckhardt BC
    J Hepatol; 2011 Mar; 54(3):513-20. PubMed ID: 21093948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1.
    Garrelfs SF; Metry EL; van Harskamp D; Vaz FM; van den Akker CHP; Schierbeek H; Groothoff JW; Oosterveld MJS
    Kidney Int; 2023 May; 103(5):990-993. PubMed ID: 36871948
    [No Abstract]   [Full Text] [Related]  

  • 40. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition.
    Riedel TJ; Knight J; Murray MS; Milliner DS; Holmes RP; Lowther WT
    Biochim Biophys Acta; 2012 Oct; 1822(10):1544-52. PubMed ID: 22771891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.